Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H17N3O.ClH |
Molecular Weight | 291.776 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(C=C1)N3CCN(C)C4=NCCC2=C34
InChI
InChIKey=RQQVSZWEVNAKGW-UHFFFAOYSA-N
InChI=1S/C15H17N3O.ClH/c1-17-7-8-18-13-4-3-10(19-2)9-12(13)11-5-6-16-15(17)14(11)18;/h3-4,9H,5-8H2,1-2H3;1H
Metralindole (Inkazan) is a reversible inhibitor of monoamine oxidase A (RIMA) which was used in Russia as an antidepressant. Inkasan (3-methyl-8-methoxy-3H, 1,2,5,6- tetrahydropyrazine /1.2.3-ab/-beta-carboline hydrochloride) has pharmacological properties characteristic of antidepressants. The clinical antidepressant effect of inkasan is combined with stimulating action. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression.
Originator
Sources: https://link.springer.com/article/10.1007/BF00781063
Curator's Comment: Inkazan (metralindole) was developed in the Ordzhonikidze All-Union Scientific-Research Pharmaceutical-Chemistry Institute
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3358 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1884793 |
|||
Target ID: CHEMBL3358 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1884793 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Inkazan Approved UseTreatment of depression. The drug is primarily indicated for patients in whom adynamic (anergic) disturbances are predominant in the clinical picture of depression. |
Sample Use Guides
In Vivo Use Guide
Sources: https://link.springer.com/article/10.1007/BF00781063
Curator's Comment: Metralindole (Inkazan) was also used orally (10 mg/kg)
https://www.ncbi.nlm.nih.gov/pubmed/2728714
Cats: Electroencephalographic investigations conducted by L. F. Roshchina showed that in cats
inkazan in doses of 10-40 mg/kg (intravenously) caused increased cortical and subcortical
activity and intensified the reaction of cortex to photo- and photon stimulation. The electrophysiological
response of inkazan persists for 3-4 h. In doses of 5-50 mg/kg administered
intraperitoneally, the preparation slows conditioned reflexes of avoidance in rats.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6276226
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID90202016
Created by
admin on Sat Dec 16 03:46:39 GMT 2023 , Edited by admin on Sat Dec 16 03:46:39 GMT 2023
|
PRIMARY | |||
|
M15TM76Y3L
Created by
admin on Sat Dec 16 03:46:39 GMT 2023 , Edited by admin on Sat Dec 16 03:46:39 GMT 2023
|
PRIMARY | |||
|
DBSALT001789
Created by
admin on Sat Dec 16 03:46:39 GMT 2023 , Edited by admin on Sat Dec 16 03:46:39 GMT 2023
|
PRIMARY | |||
|
53734-79-5
Created by
admin on Sat Dec 16 03:46:39 GMT 2023 , Edited by admin on Sat Dec 16 03:46:39 GMT 2023
|
PRIMARY | |||
|
171296
Created by
admin on Sat Dec 16 03:46:39 GMT 2023 , Edited by admin on Sat Dec 16 03:46:39 GMT 2023
|
PRIMARY | |||
|
m7501
Created by
admin on Sat Dec 16 03:46:39 GMT 2023 , Edited by admin on Sat Dec 16 03:46:39 GMT 2023
|
PRIMARY | Merck Index |
SUBSTANCE RECORD